KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Zimmer Biomet Holdings (ZBH) EBITDA Margin (2016 - 2025)

Zimmer Biomet Holdings (ZBH) has 17 years of EBITDA Margin data on record, last reported at 6.89% in Q4 2025.

  • For Q4 2025, EBITDA Margin fell 1234.0% year-over-year to 6.89%; the TTM value through Dec 2025 reached 13.34%, down 340.0%, while the annual FY2025 figure was 13.34%, 340.0% down from the prior year.
  • EBITDA Margin reached 6.89% in Q4 2025 per ZBH's latest filing, down from 17.55% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 24.17% in Q1 2021 and bottomed at 1.55% in Q4 2022.
  • Average EBITDA Margin over 5 years is 14.47%, with a median of 15.26% recorded in 2023.
  • Peak YoY movement for EBITDA Margin: skyrocketed 4974bps in 2021, then crashed -1234bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 7.53% in 2021, then plummeted by -121bps to 1.55% in 2022, then surged by 1277bps to 18.26% in 2023, then increased by 5bps to 19.23% in 2024, then plummeted by -64bps to 6.89% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 6.89% in Q4 2025, 17.55% in Q3 2025, and 14.44% in Q2 2025.